In a study presented at ACTRIMS Forum 2023, researchers assessed pregnancy outcomes and disease activity following cladribine exposure in women with MS.

Researchers sought to evaluate the demographics and clinical presentation of patients with MOGAD-related optic neuritis in a Canadian population.

In a study presented at ACTRIMS Forum 2023, researchers assessed the efficacy of treatment regimens on disability outcomes of patients with NMOSD- and MOGAD-optic neuritis and myelitis.

In a study presented at ACTRIMS Forum 2023, researchers assessed the influence of drivers on clinician considerations when choosing S1P receptor modulators to treat patients with MS.

Researchers assessed the extent to which MS rehabilitation trials considered race and ethnicity in trial and intervention processes.

In a study presented at ACTRIMS Forum 2023, researchers identified MRI volumetric biomarkers associated with concurrent disability progression in MS.

In a study presented at ACTRIMS Forum 2023, researchers assessed the relationship between global and cortex-specific structures with cognitive performance in older patients with MS.

Researchers assessed the efficacy, safety, and tolerability of glatiramer acetate (GA) Depot when given every 4 weeks in patients with relapsing forms of MS.

Researchers sought to determine the effect of long-term depletion of CD19+ B cells on childhood vaccine-generated humoral responses in participants from N-Momentum.

Researchers sought to segment and detect active and nonactive white matter MS lesions via the development of a deep learning technique.

The MSAA Advisory Board and the African American MS Advisory board gathered relevant information on the challenges faced by Black individuals with MS in getting an accurate MS diagnosis and prompt, effective treatment.

In a study presented at ACTRIMS Forum 2023, researchers determined the impact of CVD on long-term confirmed disability progression in people with MS.

In a study presented at ACTRIMS Forum 2023, researchers reported the clinical outcomes and safety of tixagevimab and cilgavimab on preventing COVID-19 in patients with MS on B-cell depleters.

In a study presented at ACTRIMS Forum 2023, researchers determined the relationships between depression or anxiety and cognition among younger and older adults with MS.

In a study presented at ACTRIMS Forum 2023, researchers compared care settings for UTI-related infections among commercially insured patients with MS and individuals without a history of MS.

In a study presented at ACTRIMS Forum 2023, researchers looked at the alterations of gut bacteria-phage interactions associated with the pathogenesis of MS.

In a cross-sectional study, researchers evaluated patterns of telemedicine usage and accessibility among commercially insured patients with MS during the COVID-19 pandemic.

In a study presented at ACTRIMS Forum 2023, researchers identified high-risk patients with MS and NMOSD for rehospitalization and associated traits and comorbidities that may predict readmission.